High dose UDCA therapy does not improve overall liver histology in obesity related hepatitis

Apr 16, 2010

Results of a German study presented today at the International Liver Congress 2010, the Annual Meeting of the European Association for the Study of Liver in Vienna, Austria, have shown that overall, treatment with high dose (23-28mg/kg/d) ursodeoxycholic acid (UDCA) is no more effective than placebo in the treatment of non-alcoholic steatohepatitis (NASH), the most advanced form of non-alcoholic liver disease associated with cirrhosis of the liver .

NASH is a serious development of non-alcoholic (NAFLD), the most common persistent liver disorder in western countries and for which there is no proven medical therapy. Results from this study show that high dose UDCA - a naturally occurring bile acid, historically used to treat gallstones - is not superior to placebo therapy. Moderate histological and biochemical improvement was only observed in a subgroup of mildly overweight male patients.

Commenting on the study, Professor Fabio Marra of the EASL scientific committee said: "The use of UDCA is still considered controversial in non-alcoholic hepatitis, although previous research has suggested that the treatment may have some beneficial effects. The results of this study indicate that high dose UDCA is not superior to placebo except in a small subset of individuals. Nevertheless, the results do provide some interesting clinical pointers for clinicians in this field."

In the study, patients with histologically proven NASH (n=186, 147 of whom proceeded to treatment) were organised according to gender, body weight, liver biochemistry and histology and were randomised to receive either 23-28mg/kg/d UDCA or placebo for a period of 18 months.

Pre- and post-treatment from 139 patients were analysed, the primary evaluation criteria was an improvement in liver histology and secondary criteria were improvements in NASH-associated histological findings and liver function test results.

No significant difference was seen in overall liver histology or biochemistries between the two treatment groups. Interestingly, beneficial results were seen in intra-acinar inflammation (inflammation of the functional units of the liver) and levels of the enzyme gamma glutamyltransferase (a marker for liver cell damage) in a small population of younger, mildly overweight males, indicating that UDCA therapy may be potentially useful for these patients.

The incidence and prevalence of NASH is increasing , in parallel with rising levels of obesity - one of the main risk factors for NASH . With this in mind, it is important to identify effective treatment options to improve the management of patients and prevent progression to cirrhosis - an irreversible condition with liver transplant the only definitive treatment.

Explore further: German medics report on drug success for Ebola patient

More information:
References:

1 Leuschner U et al., Treatment of Nonalcoholic Steatohepatitis (NASH) with high dose Ursodeoxycholic acid (UCDA). A randomized, prospective placebo-controlled multicenter study. Abstract presented at The International Liver CongressTM 2010

2Kumar Vinay, Nelso Fausto and Abul Abbas. Robbins & Cotran Pathologic Basis of Disease, Seventh Edition. Saunders, 2004

3Fatty Liver. Medicine Net. Available at www.medicinenet.com/fatty_liver/page4.htm accessed 19.03.10

4Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006 Mar; 40(3 Suppl 1): S5-10

5NASH. British Liver Trust. Available at www.britishlivertrust.org.uk/h… ohepatitis-nash.aspx accessed 19.03.10

Provided by European Association for the Study of the Liver

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Mayo Clinic seeks new therapies for alcoholic hepatitis

Dec 01, 2008

A new study from Mayo Clinic finds the use of the drug therapy etanercept ineffective in treating alcoholic hepatitis, an acute inflammation of the liver caused by excessive consumption of alcohol. The results of the study ...

New data emerges on liver transplant survival rates

Nov 25, 2009

Researchers at the University of Miami School of Medicine compared the outcomes of cirrhotic patients who underwent liver transplants for nonalcoholic steatohepatitis (NASH) versus alcoholic liver disease (ETOH) and found ...

Recommended for you

Evidence-based recs issued for systemic care in psoriasis

14 hours ago

(HealthDay)—For appropriately selected patients with psoriasis, combining biologics with other systemic treatments, including phototherapy, oral medications, or other biologic, may result in greater efficacy ...

Bacteria in caramel apples kills at least four in US

14 hours ago

A listeria outbreak believed to originate from commercially packaged caramel apples has killed at least four people in the United States and sickened 28 people since November, officials said Friday.

Steroid-based treatment may answer needs of pediatric EoE patients

15 hours ago

A new formulation of oral budesonide suspension, a steroid-based treatment, is safe and effective in treating pediatric patients with eosinophilic esophagitis (EoE), according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal ...

Discovery of genes that predispose a severe form of COPD

17 hours ago

A study by Ramcés Falfán-Valencia, researcher at the National Institute of Respiratory Diseases (INER), found that the mestizo Mexican population has a number of variations in certain genes that predispose ...

On the environmental trail of food pathogens

18 hours ago

Tracking one of the deadliest food contamination organisms through produce farms and natural environments alike, Cornell microbiologists are showing how to use big datasets to predict where the next outbreak could start.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.